Period-specific differences in clinical characteristics of hospitalized children with Epstein–Barr virus infection: a single-center retrospective study

Objective This study aimed to compare the demographic characteristics, laboratory parameters, major clinical complications, and comorbidities of hospitalized children with Epstein–Barr virus (EBV) infection across three calendar periods—2018–2019, 2020–2022, and 2023–2025—and to describe temporal changes in the characteristics of hospitalized cases during periods broadly overlapping with different phases of the COVID-19 pandemic. Methods The study period was divided into three calendar periods: 2018–2019, 2020–2022, and 2023–2025, which broadly overlapped with different phases of the COVID-19 pandemic. This temporal classification was used solely to describe period-specific differences in the clinical and laboratory characteristics of hospitalized children with EBV infection and was not intended to infer causal effects of the COVID-19 pandemic or related public health measures on EBV infection. The numbers of hospitalized children included in the three periods were 39, 96, and 307, respectively, resulting in marked imbalance in group sizes. Annual case numbers also varied substantially, with 4 cases in 2018, 35 in 2019, 2 in 2020, 21 in 2021, 73 in 2022, and 117, 119, and 71 cases in 2023, 2024, and 2025, respectively. Results The age distribution differed across periods (χ² = 20.07, P < 0.001), with older children accounting for a larger proportion in 2023–2025. EBV nuclear antigen antibody and viral capsid antigen IgG levels were higher in 2020–2022 than in the other periods, whereas plasma EBV-DNA levels were lower. Infection-status classification was available for 267 children, with substantial differences in data completeness across periods. Non-severe pneumonia showed a nominal period difference (P = 0.046); no statistically significant differences were detected for the other evaluated clinical outcomes. Documented coinfection occurred in 206 children (46.61%) and was associated with higher odds of non-severe pneumonia (OR = 2.63, 95% CI: 1.79–3.87) and severe pneumonia (OR = 5.23, 95% CI: 1.47–18.62), but lower odds of liver function impairment (OR = 0.31, 95% CI: 0.15–0.68). Hospitalization costs were higher in 2023–2025. Conclusion Across the three calendar periods broadly overlapping with different phases of the COVID-19 pandemic, hospitalized children with EBV infection showed temporal differences in age distribution, selected laboratory parameters, and the distribution of EBV infection status. Infection-status analysis indicated a lower proportion of acute primary infection in 2020–2022 than in 2023–2025; however, this finding should be interpreted cautiously because of differences in the completeness of infection-status classification across periods. These findings reflect period-specific characteristics of hospitalized children and should not be interpreted as evidence of changes in EBV epidemiology in the general pediatric population.

Authors

Institutions

Publication Details

Journal
BMC Infectious Diseases
Published
2026-11-18
DOI
https://doi.org/10.1186/s12879-026-14627-2
Primary Topic
Viral-associated cancers and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Period-specific differences in clinical characteristics of hospitalized children with Epstein–Barr virus infection: a single-center retrospective study

Jianwei Zhang, Jiahui Hu, Tao Zhan²⁺,, Zheng Zhang¹⁺,
3 links
BMC Infectious Diseases
Viral-associated cancers and disorders
article

Period-specific differences in clinical characteristics of hospitalized children with Epstein–Barr virus infection: a single-center retrospective study

Jianwei Zhang, Jiahui Hu, Tao Zhan²⁺,, Zheng Zhang¹⁺,
article en

Abstract

Objective This study aimed to compare the demographic characteristics, laboratory parameters, major clinical complications, and comorbidities of hospitalized children with Epstein–Barr virus (EBV) infection across three calendar periods—2018–2019, 2020–2022, and 2023–2025—and to describe temporal changes in the characteristics of hospitalized cases during periods broadly overlapping with different phases of the COVID-19 pandemic. Methods The study period was divided into three calendar periods: 2018–2019, 2020–2022, and 2023–2025, which broadly overlapped with different phases of the COVID-19 pandemic. This temporal classification was used solely to describe period-specific differences in the clinical and laboratory characteristics of hospitalized children with EBV infection and was not intended to infer causal effects of the COVID-19 pandemic or related public health measures on EBV infection. The numbers of hospitalized children included in the three periods were 39, 96, and 307, respectively, resulting in marked imbalance in group sizes. Annual case numbers also varied substantially, with 4 cases in 2018, 35 in 2019, 2 in 2020, 21 in 2021, 73 in 2022, and 117, 119, and 71 cases in 2023, 2024, and 2025, respectively. Results The age distribution differed across periods (χ² = 20.07, P < 0.001), with older children accounting for a larger proportion in 2023–2025. EBV nuclear antigen antibody and viral capsid antigen IgG levels were higher in 2020–2022 than in the other periods, whereas plasma EBV-DNA levels were lower. Infection-status classification was available for 267 children, with substantial differences in data completeness across periods. Non-severe pneumonia showed a nominal period difference (P = 0.046); no statistically significant differences were detected for the other evaluated clinical outcomes. Documented coinfection occurred in 206 children (46.61%) and was associated with higher odds of non-severe pneumonia (OR = 2.63, 95% CI: 1.79–3.87) and severe pneumonia (OR = 5.23, 95% CI: 1.47–18.62), but lower odds of liver function impairment (OR = 0.31, 95% CI: 0.15–0.68). Hospitalization costs were higher in 2023–2025. Conclusion Across the three calendar periods broadly overlapping with different phases of the COVID-19 pandemic, hospitalized children with EBV infection showed temporal differences in age distribution, selected laboratory parameters, and the distribution of EBV infection status. Infection-status analysis indicated a lower proportion of acute primary infection in 2020–2022 than in 2023–2025; however, this finding should be interpreted cautiously because of differences in the completeness of infection-status classification across periods. These findings reflect period-specific characteristics of hospitalized children and should not be interpreted as evidence of changes in EBV epidemiology in the general pediatric population.

BMC Infectious Diseases
Shaoxing City Women and Children Hospital (CN)
Good health and well-being
Viral-associated cancers and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon